Friday, October 3, 2025

The Overdose Unknown: The General Approach

 

The Overdose Unknown: The General Approach to the Poisoned Patient

Dr Neeraj Manikath , claude.ai

Abstract

Acute poisoning represents a significant challenge in critical care, with over 2 million toxic exposures reported annually to poison control centers in the United States alone. The poisoned patient often presents with an unclear history, multiple substance exposures, and rapidly evolving clinical manifestations. This review provides a systematic, evidence-based approach to the management of the undifferentiated poisoned patient, emphasizing the primacy of supportive care, toxidrome recognition, and judicious use of antidotes. We integrate current guidelines with practical clinical pearls to guide the postgraduate trainee through the critical first hours of managing these complex patients.

Keywords: Toxicology, poisoning, toxidrome, antidotes, critical care, overdose


Introduction

The emergency department and intensive care unit serve as the front lines for managing acute poisonings, yet the majority of clinicians receive limited formal training in clinical toxicology. The undifferentiated poisoned patient presents a unique diagnostic challenge: the substance may be unknown, co-ingestions are common (occurring in 30-50% of intentional overdoses), and the clinical presentation may not manifest for hours after exposure.[1,2]

The fundamental principle guiding the management of any poisoned patient is deceptively simple: excellent supportive care saves more lives than any specific antidote. Most patients survive toxic exposures through meticulous attention to airway management, hemodynamic support, and prevention of secondary complications. This review focuses on the systematic approach to the patient with an unknown overdose, providing a framework applicable to virtually any poisoning scenario.

Pearl: The mnemonic "ABCDE" in toxicology stands for: Airway, Breathing, Circulation, Decontamination, and Enhanced Elimination—a framework that organizes priorities even when the toxin remains unknown.


The Primary Survey: Airway, Breathing, and the Glasgow Coma Scale

Airway Assessment and Management

The first priority in any poisoned patient is airway assessment. Altered mental status occurs in approximately 15-20% of serious poisonings and represents the most common indication for intensive care admission.[3] Unlike trauma scenarios where cervical spine protection dominates airway management, the poisoned patient's airway concerns center on three mechanisms:

  1. Central nervous system depression leading to loss of protective reflexes
  2. Hypersalivation or secretions (particularly with cholinergic or sedative toxins)
  3. Seizures compromising airway patency

The decision to intubate a poisoned patient should be based on clinical assessment rather than an arbitrary Glasgow Coma Scale (GCS) cutoff. Traditional teaching suggests intubation for GCS ≤8, but this rule lacks validation in the toxicology literature. Instead, assess for:

  • Inability to protect the airway (absent gag reflex, pooling secretions)
  • Inadequate ventilation (respiratory acidosis, hypoxemia)
  • Anticipated clinical deterioration (large ingestion of delayed-release formulation, progressive symptoms)
  • Need for decontamination procedures (gastric lavage, though rarely indicated)

Hack: Before reaching for the laryngoscope, consider temporizing measures. Naloxone can rapidly reverse opioid-induced respiratory depression and may obviate intubation. Similarly, repositioning and basic airway maneuvers buy time for assessment while antidotes take effect.

Oyster: Avoid succinylcholine in poisoned patients when possible, particularly with organophosphate exposure. These patients have depleted pseudocholinesterase levels, leading to prolonged paralysis.[4] Rocuronium with sugammadex reversal offers a safer alternative with predictable offset.

Breathing and Ventilation

Once the airway is secured (or preserved), assess ventilation adequacy. Several toxins cause distinctive respiratory patterns:

  • Respiratory depression: Opioids, sedative-hypnotics, barbiturates
  • Tachypnea: Salicylates (respiratory alkalosis initially), toxic alcohols, sympathomimetics
  • Bradypnea: Clonidine, opioids, GHB

Arterial blood gas analysis provides critical information beyond oxygenation status. The anion gap metabolic acidosis serves as a red flag for specific toxins, remembered by the mnemonic GOLDMARK:

  • Glycols (ethylene glycol, propylene glycol)
  • Oxoproline (from chronic acetaminophen use)
  • L-lactate (from metformin, cyanide, carbon monoxide, seizures)
  • D-lactate (propylene glycol, short bowel syndrome)
  • Methanol
  • Aspirin (salicylates)
  • Renal failure (uremia)
  • Ketoacidosis (alcoholic, diabetic, starvation)

Pearl: Calculate the osmolar gap in any patient with unexplained altered mental status and anion gap metabolic acidosis. An osmolar gap >10 mOsm/kg suggests toxic alcohol ingestion (methanol, ethylene glycol, isopropanol). The formula: Osmolar gap = Measured osmolality - Calculated osmolality, where Calculated osmolality = 2(Na+) + (Glucose/18) + (BUN/2.8) + (Ethanol/4.6).[5]

Glasgow Coma Scale and Mental Status Assessment

The GCS, while imperfect, provides a standardized method for documenting and tracking mental status changes. However, in toxicology, the trajectory matters more than the absolute number. Document:

  • Pupil size and reactivity (critical for toxidrome identification)
  • Response to naloxone or flumazenil (if administered)
  • Temporal progression (improving, stable, or deteriorating)

Serial assessments every 15-30 minutes in the acute phase can guide management decisions and predict the need for escalation of care.

Hack: The "Talk Test" provides a rapid functional assessment: Can the patient state their name, location, and follow simple commands? If yes, the airway is likely patent, ventilation adequate, and perfusion sufficient to maintain consciousness—buying time for further evaluation.


The Toxidrome Recognition: Opioid, Sympathomimetic, Anticholinergic, Cholinergic, Sedative

Toxidrome recognition represents the cornerstone of clinical toxicology. A toxidrome is a constellation of signs and symptoms that suggest exposure to a particular class of substances, allowing for rational empiric therapy even when the specific agent remains unknown.[6] While many poisonings present with mixed or atypical features, recognizing classic patterns guides initial management.

The Opioid Toxidrome

Classic Triad: Miosis, respiratory depression, decreased level of consciousness

Mechanism: Mu-opioid receptor agonism in the CNS, causing decreased respiratory drive, altered consciousness, and miosis through Edinger-Westphal nucleus effects.

Clinical Features:

  • Pinpoint pupils (1-2mm) reactive to light
  • Respiratory rate <12/min with decreased tidal volume
  • GCS typically 3-10
  • Decreased bowel sounds
  • Hypothermia (from reduced thermogenesis)
  • Track marks or other stigmata of injection drug use

Expanded Differential:

  • Prescription opioids: morphine, oxycodone, hydrocodone, fentanyl
  • Illicit opioids: heroin, illicit fentanyl analogs, carfentanil
  • Atypical opioids: tramadol (also inhibits serotonin/norepinephrine reuptake), tapentadol
  • Opioid-like substances: clonidine, loperamide (in massive overdose)

Pearl: Not all CNS depressants cause miosis. If pupils are normal or dilated with respiratory depression, consider co-ingestion, hypoxic brain injury, or non-opioid sedatives. Meperidine can paradoxically cause mydriasis due to anticholinergic properties.

Oyster: Massive exposure to synthetic opioids (fentanyl, carfentanil) may require milligrams rather than micrograms of naloxone. Chest wall rigidity can occur with rapid IV fentanyl administration, preventing ventilation despite an open airway—this requires paralysis and intubation, not just naloxone.[7]

The Sympathomimetic Toxidrome

Classic Features: Hypertension, tachycardia, hyperthermia, mydriasis, diaphoresis, agitation

Mechanism: Excessive adrenergic stimulation through various mechanisms—increased catecholamine release (amphetamines, cocaine), decreased reuptake (cocaine), direct receptor agonism (synthetic cathinones), or MAO inhibition.

Clinical Features:

  • Vital signs: HR >100 bpm, BP often >160/100 mmHg, temperature >38.5°C
  • Dilated pupils (4-8mm) reactive to light
  • Diaphoretic skin (wet)
  • Hyperreflexia, tremor, myoclonus
  • Agitation, paranoia, hallucinations
  • Mydriasis with horizontal nystagmus suggests phencyclidine (PCP)

Agents:

  • Classical stimulants: cocaine, amphetamines, methamphetamine
  • Substituted amphetamines: MDMA (ecstasy), methylone
  • Synthetic cathinones: bath salts, mephedrone
  • Over-the-counter: pseudoephedrine, caffeine (massive doses)
  • Prescription: phentermine, methylphenidate, bupropion
  • Withdrawal states: alcohol, benzodiazepines

Pearl: The presence of diaphoresis distinguishes sympathomimetic from anticholinergic toxidromes—both cause tachycardia, hypertension, and mydriasis, but anticholinergic patients have dry, flushed skin.

Hack: Benzodiazepines are first-line for sympathomimetic toxicity. Titrate large doses (midazolam 0.1-0.2 mg/kg IV bolus, repeated as needed) to control agitation, which reduces oxygen consumption, heat generation, and cardiovascular stress. Avoid beta-blockers as monotherapy—unopposed alpha stimulation can worsen hypertension.[8]

The Anticholinergic Toxidrome

Classic Description: "Blind as a bat, red as a beet, hot as a hare, dry as a bone, mad as a hatter"

Mechanism: Muscarinic acetylcholine receptor antagonism, causing both central and peripheral effects.

Clinical Features:

  • Central: Agitation, confusion, delirium, hallucinations (often visual), mumbling speech, myoclonus, seizures
  • Peripheral:
    • Mydriasis (dilated pupils 6-9mm, poorly reactive or non-reactive)
    • Dry mucous membranes, decreased secretions
    • Decreased or absent bowel sounds
    • Urinary retention
    • Flushed, dry skin
    • Hyperthermia (from inability to sweat)
    • Tachycardia (from vagal blockade)

Agents:

  • Antihistamines: diphenhydramine, hydroxyzine, doxylamine
  • Psychiatric medications: tricyclic antidepressants, olanzapine, clozapine
  • Antiparkinson drugs: benztropine, trihexyphenidyl
  • Antispasmodics: oxybutynin, dicyclomine
  • Plants: jimsonweed (Datura), deadly nightshade (Atropa belladonna)
  • Mushrooms: Amanita muscaria
  • Over-the-counter sleep aids: most contain diphenhydramine

Oyster: Tricyclic antidepressants deserve special mention—they cause anticholinergic effects PLUS sodium channel blockade (causing QRS widening and arrhythmias) and alpha-blockade (hypotension). A QRS >100 ms predicts seizures, and >160 ms predicts ventricular arrhythmias. Sodium bicarbonate (bolus 1-2 mEq/kg) is the specific treatment for TCA-induced cardiac toxicity.[9]

Pearl: Central anticholinergic syndrome can occur with therapeutic doses of medications in susceptible populations (elderly, polypharmacy). Consider this diagnosis in elderly patients with acute delirium—particularly if they recently started an antihistamine, bladder medication, or muscle relaxant.

The Cholinergic Toxidrome

Classic Features: SLUDGE syndrome (Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis) plus the "Killer Bs" (Bronchospasm, Bronchorrhea, Bradycardia)

Mechanism: Excess acetylcholine at muscarinic and nicotinic receptors, typically from acetylcholinesterase inhibition.

Clinical Features:

Muscarinic effects:

  • Increased secretions (salivation, lacrimation, bronchorrhea)
  • Miosis (pinpoint pupils)
  • Bronchospasm, bronchorrhea
  • Bradycardia
  • Urination, defecation
  • Emesis
  • Diaphoresis (although sweating is technically nicotinic)

Nicotinic effects:

  • Muscle fasciculations followed by weakness or paralysis
  • Tachycardia (early, from sympathetic ganglia stimulation)
  • Hypertension
  • Mydriasis (can occur early, confusing the picture)

Central effects:

  • Anxiety, confusion, coma
  • Seizures
  • Respiratory depression

Agents:

  • Organophosphate insecticides (malathion, parathion, chlorpyrifos)
  • Carbamate insecticides (aldicarb, carbaryl)
  • Nerve agents (sarin, VX, soman)
  • Medications: physostigmine, pyridostigmine, donepezil, rivastigmine
  • Certain mushrooms: Inocybe and Clitocybe species

Pearl: The "two PAMs and an atropine" approach for organophosphate poisoning: Pralidoxime (2-PAM) 1-2 g IV over 30 minutes, repeated as needed, reactivates acetylcholinesterase if given early (<24-48 hours). Atropine 2-5 mg IV bolus, doubled every 5 minutes until bronchial secretions dry (may require hundreds of milligrams). Think of atropine as "drying the patient" rather than treating by vital signs.[10]

Hack: In resource-limited settings or with delayed presentation beyond the pralidoxime window, high-dose atropine alone can be life-saving. The endpoint is dried bronchial secretions, not pupil size or heart rate.

The Sedative-Hypnotic Toxidrome

Classic Features: CNS depression, respiratory depression, normal pupils, normal or decreased temperature

Mechanism: Enhancement of GABA-A receptor function (benzodiazepines, barbiturates) or other CNS depressant mechanisms.

Clinical Features:

  • Decreased level of consciousness (GCS variable, 3-14)
  • Respiratory depression (rate and/or tidal volume)
  • Normal or slightly dilated pupils (3-5mm), reactive
  • Hypotension (with massive overdose or barbiturates)
  • Hypothermia
  • Decreased or normal reflexes
  • Normal bowel sounds

Agents:

  • Benzodiazepines: diazepam, alprazolam, clonazepam, lorazepam
  • Barbiturates: phenobarbital, butalbital
  • Non-benzodiazepine hypnotics: zolpidem, eszopiclone, zaleplon
  • Gamma-hydroxybutyrate (GHB) and precursors
  • Ethanol
  • Baclofen
  • Carisoprodol (metabolizes to meprobamate)

Distinguishing from Opioids:

  • Normal-sized pupils (not miotic)
  • Less profound respiratory depression per degree of sedation
  • Slower onset (most sedatives have longer time to peak effect than opioids)
  • Context clues (prescription bottles, known anxiety disorder history)

Pearl: GHB deserves special mention—it causes profound but brief CNS depression (often GCS 3-4), typically resolving spontaneously within 2-6 hours. Patients may require intubation but wake precipitously, becoming agitated and attempting self-extubation. Bradycardia is common. The key is supportive care; most patients can be managed with close observation rather than intubation if respiratory drive remains adequate.[11]

Oyster: Benzodiazepine tolerance means that patients on chronic benzodiazepines may ingest quantities that would be lethal to opioid-naive individuals yet present with minimal symptoms. Conversely, benzodiazepine-naive patients may experience profound CNS depression from therapeutic doses.

Mixed and Atypical Toxidromes

Clinical reality rarely matches textbook toxidromes perfectly. Consider:

  • Serotonin syndrome: Hyperthermia, clonus, hyperreflexia, autonomic instability—overlaps with sympathomimetic but has distinctive neuromuscular hyperactivity (particularly ocular clonus and lower extremity clonus)
  • Neuroleptic malignant syndrome: Rigidity (lead-pipe), hyperthermia, altered mental status—develops over days, not hours
  • Salicylate toxicity: Mixed acid-base disturbances (respiratory alkalosis plus anion gap metabolic acidosis), tinnitus, hyperpnea
  • Toxic alcohol ingestion: Osmolar gap early, anion gap later, visual symptoms (methanol), flank pain (ethylene glycol)

Hack: When the presentation doesn't fit a classic toxidrome, consider: (1) co-ingestion, (2) complications of the ingestion (hypoxic brain injury, aspiration, rhabdomyolysis), (3) non-toxicologic etiology, or (4) rare poison.


The Universal Antidotes: Naloxone, Flumazenil, Deferoxamine, N-Acetylcysteine

The term "universal antidotes" is a misnomer—no antidote applies to all poisonings—but certain antidotes have such broad applicability or critical importance that every intensivist must know them intimately.

Naloxone: The Opioid Reversal Agent

Mechanism: Competitive antagonist at mu, kappa, and delta opioid receptors

Indications:

  • Suspected opioid toxicity with respiratory depression (RR <10-12/min)
  • Altered mental status with miosis in appropriate context
  • Diagnostic trial in undifferentiated coma with respiratory depression

Dosing:

  • Initial: 0.04-0.4 mg IV (40-400 mcg), titrated to respiratory effort, NOT full consciousness
  • Goal: Adequate ventilation and airway protection, not complete reversal
  • Escalation: Double the dose every 2-3 minutes if no response (up to 10-15 mg total for suspected synthetic opioid overdose)
  • Infusion: If repeat boluses needed, start continuous infusion at two-thirds of the effective bolus dose per hour (e.g., if 2 mg total bolus was effective, infuse 1.3 mg/hr)

Routes of Administration:

  • IV: Preferred, onset 1-2 minutes
  • IM/SC: Onset 5-10 minutes, useful in prehospital setting
  • Intranasal: 2-4 mg (absorbed transmucosally), onset 5-10 minutes
  • Endotracheal: 2-2.5× IV dose (rarely necessary with IN availability)

Duration: 30-90 minutes (shorter than most opioids), necessitating observation for renarcotization

Pearl: Titrate to respiratory effort, not consciousness. The goal of naloxone is to restore adequate spontaneous ventilation, not to achieve full alertness. Over-reversal precipitates acute opioid withdrawal (agitation, tachycardia, hypertension, vomiting), increases the risk of aspiration, and may cause the patient to abscond before evaluation is complete.

Oyster: Naloxone does not reverse buprenorphine effectively at standard doses due to buprenorphine's high receptor affinity and slow dissociation. Massive doses (10-15 mg) may be required, or mechanical ventilation may be necessary until buprenorphine redistributes.[12]

Controversy: The proliferation of synthetic opioids (illicit fentanyl analogs) has changed prehospital and emergency naloxone use. Some patients require unprecedented doses, and case reports describe naloxone doses exceeding 20 mg. This has led to debate about appropriate initial dosing—should we start higher? Current consensus favors starting low (preserving the option for partial reversal) but being prepared to escalate rapidly and dramatically.[7]

Hack: If you suspect opioid overdose but naloxone is unavailable (or while preparing it), bag-valve-mask ventilation is the immediate life-saving intervention. Opioid-induced respiratory depression responds well to positive pressure ventilation, and adequate oxygenation prevents anoxic brain injury while definitive treatment is prepared.

Flumazenil: The Controversial Benzodiazepine Antagonist

Mechanism: Competitive antagonist at the GABA-A benzodiazepine receptor

Indications (controversial):

  • Accepted: Iatrogenic benzodiazepine oversedation (procedure-related)
  • Controversial: Suspected isolated benzodiazepine overdose

Dosing:

  • Initial: 0.2 mg IV over 30 seconds
  • Repeat: 0.3 mg at 1 minute if no response
  • Further: 0.5 mg every 1 minute up to cumulative 3 mg
  • Infusion: 0.1-0.5 mg/hr if repeat boluses required

Duration: 40-80 minutes (shorter than most benzodiazepines)

Contraindications (relative and absolute):

  • Seizure disorder or risk: Removes GABA-ergic anticonvulsant effect
  • Chronic benzodiazepine use: Precipitates withdrawal seizures
  • Co-ingestion with pro-convulsant (TCAs, cocaine, tramadol, bupropion): Unmasks seizure activity
  • Increased intracranial pressure: Benzodiazepine effect may be protective
  • QRS widening on ECG: Suggests TCA co-ingestion

Oyster: Flumazenil is rarely indicated in the poisoned patient. Unlike naloxone, which addresses life-threatening respiratory depression, isolated benzodiazepine overdose rarely causes death with supportive care. The risk of precipitating seizures (potentially refractory status epilepticus) in unrecognized polypharmacy overdose outweighs benefits in most scenarios.[13]

When to Consider: The narrow window for flumazenil use includes:

  1. Known iatrogenic benzodiazepine administration (post-procedure)
  2. Confirmed isolated benzodiazepine ingestion (witnessed, confirmatory testing)
  3. No seizure history or pro-convulsant co-ingestion
  4. Hemodynamic stability

Pearl: In cases of suspected hepatic encephalopathy with benzodiazepine contribution, flumazenil may clarify mental status and guide further management. However, this is best done in consultation with toxicology or hepatology specialists.

Hack: The best approach to benzodiazepine overdose is supportive care—airway protection if needed, monitoring for aspiration, and allowing time for metabolism and elimination. Most patients awaken within 12-24 hours without intervention.

Deferoxamine: The Iron Chelator

Mechanism: Binds free iron, forming ferrioxamine, which is renally excreted

Indications:

  • Confirmed: Serum iron >500 mcg/dL
  • Empiric: Suspected significant iron ingestion with clinical toxicity (persistent vomiting, hematemesis, shock, altered mental status, metabolic acidosis)
  • Consider: Serum iron 350-500 mcg/dL with symptoms

Dosing:

  • Continuous IV infusion: 15 mg/kg/hr (maximum 6-8 g/24hr traditionally, though higher doses used in severe toxicity)
  • Duration: Until clinical improvement and iron level <100 mcg/dL, typically 12-48 hours

Monitoring:

  • Serum iron levels every 4-6 hours
  • Urine color (classically "vin rosé" or rust-colored from ferrioxamine excretion, though absence doesn't exclude efficacy)
  • Metabolic acidosis resolution
  • Vital sign normalization

Pearl: The traditional "vin rosé" urine color from ferrioxamine is neither sensitive nor specific for the need to continue deferoxamine. Base decisions on clinical status (resolution of acidosis, hemodynamic stability) and decreasing iron levels rather than urine color alone.[14]

Oyster: Deferoxamine can cause acute respiratory distress syndrome (ARDS) with prolonged administration (>24-48 hours), particularly at higher doses. This mandates careful risk-benefit assessment and aggressive supportive lung care. Consider consultation with a medical toxicologist for severe cases requiring extended chelation.

Stages of Iron Toxicity:

  1. Stage I (0.5-6 hours): GI symptoms (vomiting, diarrhea, abdominal pain, hematemesis)
  2. Stage II (6-24 hours): Apparent recovery (latent phase)
  3. Stage III (12-48 hours): Shock, metabolic acidosis, coagulopathy, hepatotoxicity
  4. Stage IV (2-6 weeks): Gastric outlet obstruction from scarring

Hack: In the child with suspected iron ingestion, abdominal radiography can help. Iron tablets are radiopaque, and the presence of multiple tablets warrants aggressive decontamination (whole bowel irrigation) even before serum levels return.

N-Acetylcysteine (NAC): The Acetaminophen Antidote

Mechanism: Replenishes glutathione stores, provides alternative substrate for NAPQI (toxic metabolite), and has antioxidant and anti-inflammatory effects

Indications:

  • Confirmed: Acute acetaminophen ingestion with level above treatment line on Rumack-Matthew nomogram (4-hour level >150 mcg/mL)
  • Empiric: Suspected toxic ingestion (>7.5 g or >150 mg/kg in adults) with delayed presentation where levels cannot be interpreted
  • Extended-release or chronic: Cannot use nomogram; treat if any measurable level with suspicion of toxic ingestion
  • Uncertain timing: Treat if any detectable acetaminophen level and suspicion of overdose

Traditional 21-Hour IV Protocol (FDA-approved in US):

  • Loading dose: 150 mg/kg in 200 mL D5W over 1 hour
  • Second dose: 50 mg/kg in 500 mL D5W over 4 hours
  • Third dose: 100 mg/kg in 1000 mL D5W over 16 hours
  • Total: 300 mg/kg over 21 hours

Modified Protocols:

  • 12-hour protocol: Used in some countries, equivalent efficacy for most patients
  • Extended therapy: Continue 100 mg/kg over 16 hours (repeat third dose) if:
    • Acetaminophen level still detectable
    • AST/ALT rising or peaked but not improving
    • Massive ingestion
    • Evidence of hepatotoxicity

Oral NAC Protocol (alternative when IV unavailable):

  • Loading dose: 140 mg/kg PO
  • Maintenance: 70 mg/kg PO every 4 hours for 17 additional doses (total 72 hours)
  • Limitations: Vomiting (may require antiemetics or NG tube), slower absorption

Pearl: When in doubt, treat. NAC has an exceptional safety profile (anaphylactoid reactions occur but are rarely serious), and hepatotoxicity from untreated acetaminophen overdose carries significant morbidity and mortality. The mnemonic "Better NAC than sorry" captures this principle.

Oyster: Anaphylactoid reactions to IV NAC occur in 10-20% of patients, typically during the loading dose (which has the highest infusion rate). Reactions include flushing, urticaria, angioedema, bronchospasm, and hypotension. Management:

  1. Stop the infusion temporarily
  2. Administer antihistamines (diphenhydramine 25-50 mg IV, ranitidine 50 mg IV)
  3. For bronchospasm: Albuterol nebulizer
  4. For hypotension: Fluid bolus
  5. Resume NAC at slower rate once reaction resolves

True IgE-mediated anaphylaxis is exceedingly rare; these are rate-related histamine-release reactions, and NAC can almost always be continued at a slower rate.[15]

Hack: For patients presenting >24 hours after ingestion with established hepatotoxicity (transaminitis, coagulopathy, encephalopathy), extend NAC therapy beyond the standard 21 hours. Continue NAC infusion at 100 mg/kg over 16 hours (repeating the third dose) until clinical improvement occurs (normalizing transaminases, improving coagulopathy, improving mental status). Some patients require NAC for days to weeks until liver function recovers or transplantation occurs.[16]

Rumack-Matthew Nomogram Limitations:

  • Only valid for acute, single-time-point ingestions
  • Cannot be used if timing uncertain
  • Not applicable to chronic or repeated supratherapeutic ingestion
  • 4-hour level must be drawn at least 4 hours post-ingestion (earlier levels cannot be interpreted)

Alternative Approach for Extended-Release Acetaminophen:

  • Obtain levels at 4 hours AND 8 hours post-ingestion
  • Treat if either level is above treatment line
  • The second level captures delayed absorption

Enhanced Elimination: The Role of Activated Charcoal and Urine Alkalinization

While preventing absorption and enhancing elimination sound appealing, these interventions have narrower indications than historically believed. The era of aggressive gastric emptying (ipecac, gastric lavage) has largely passed, replaced by selective use of activated charcoal and targeted manipulation of elimination kinetics.

Gastrointestinal Decontamination

Activated Charcoal

Mechanism: Adsorbs toxins in the GI tract through Van der Waals forces, preventing systemic absorption

Dose:

  • Adults: 50-100 g PO or via NG tube
  • Children: 1 g/kg (maximum 50 g)
  • Given as aqueous slurry (typically premixed formulations)

Indications:

  • Potentially toxic ingestion of adsorbable substance
  • Timing: Most effective within 1 hour of ingestion, but may offer benefit up to 2-4 hours for:
    • Agents delaying gastric emptying (anticholinergics, opioids)
    • Sustained-release formulations
    • Large ingestions with delayed absorption
    • Substances with enterohepatic recirculation

Substances NOT adsorbed by activated charcoal (mnemonic: PHAILS):

  • Petroleum distillates (gasoline, kerosene)
  • Heavy metals (iron, lead, lithium)
  • Acids and alkalis (caustics)
  • Ions (lithium, potassium)
  • Liquid hydrocarbons
  • Solvents (alcohols, glycols)

Contraindications:

  • Absolute:
    • Unprotected airway with altered mental status (aspiration risk)
    • GI perforation or obstruction
    • Caustic ingestion
  • Relative:
    • Recent GI surgery
    • Ingestion of substance not adsorbed by charcoal
    • Presentation >2 hours after ingestion of typical-release formulation

Pearl: The risk-benefit calculation for activated charcoal hinges on aspiration risk. A patient with GCS <10 who cannot protect their airway should either be intubated before charcoal administration or charcoal should be foregone. Charcoal aspiration causes severe pneumonitis with high mortality.[17]

Multiple-Dose Activated Charcoal (MDAC):

Used to enhance elimination of certain drugs through "gastrointestinal dialysis"—interrupting enterohepatic/enteroenteric recirculation.

Indications:

  • Carbamazepine
  • Dapsone
  • Phenobarbital
  • Quinine
  • Theophylline
  • Possibly: salicylates, valproic acid

Dosing:

  • 25-50 g every 2-4 hours (adult)
  • 0.5 g/kg every 2-4 hours (pediatric)
  • Continue until clinical improvement or drug levels decline

Monitoring: Bowel sounds and stool output (ensure charcoal passage, avoid obstruction)

Oyster: MDAC is underutilized in modern practice, partly due to limited evidence from randomized trials and partly due to concerns about patient tolerability. However, for specific life-threatening ingestions (carbamazepine causing refractory seizures, theophylline causing ventricular arrhythmias), MDAC can significantly reduce drug levels and improve outcomes when extracorporeal methods are unavailable or delayed.[18]

Hack: Pre-medicate with ondansetron (4-8 mg IV) before charcoal administration to reduce vomiting. Vomiting charcoal increases aspiration risk and reduces efficacy. If the patient vomits the first dose, repeat it—one successful dose is better than none.

Gastric Lavage: The Dying Art

Once a cornerstone of poisoning management, gastric lavage has fallen from favor due to:

  • Limited efficacy (retrieves <30% of gastric contents even when performed immediately)
  • Significant complications (esophageal perforation, aspiration, vagal stimulation)
  • No mortality benefit in clinical trials

Current Limited Indications:

  • Life-threatening ingestion within 1 hour
  • No safer alternative available
  • Substance not adsorbed by charcoal
  • Protected airway (intubated)

Technique (if performed):

  • Large-bore orogastric tube (36-40 French in adults)
  • Left lateral decubitus position, head down
  • Aspirate gastric contents
  • Lavage with 200-300 mL aliquots of normal saline until clear (typically 2-5 L total)
  • Administer activated charcoal through tube after lavage

Pearl: Gastric lavage is essentially obsolete for most poisonings. The phrase "treat the patient, not the poison" encapsulates modern toxicology—supportive care outperforms aggressive decontamination in virtually all scenarios.

Whole Bowel Irrigation (WBI)

Mechanism: Large-volume polyethylene glycol electrolyte solution flushes GI tract without fluid/electrolyte shifts

Indications:

  • Body packers/stuffers: Cocaine, heroin packets
  • Sustained-release formulations: Calcium channel blockers, iron
  • Substances not adsorbed by charcoal: Iron, lithium, lead
  • Massive ingestions where tablet burden exceeds charcoal capacity

Dosing:

  • Adults: 1.5-2 L/hour via NG tube until rectal effluent clear
  • Children: 25-40 mL/kg/hour
  • Continue until clear rectal effluent (typically 4-6 hours)

Contraindications:

  • Bowel obstruction or perforation
  • GI bleeding
  • Hemodynamic instability
  • Unprotected airway
  • Ileus

Oyster: WBI creates a logistical challenge—patients require frequent bedside nursing for bowel management, and the large fluid volumes raise aspiration concerns. Place patients on a commode or use rectal tubes for containment. Ensure adequate airway protection before initiating.

Hack: For iron ingestion where abdominal radiograph shows retained tablets after initial charcoal, WBI can mechanically remove iron tablets that charcoal cannot adsorb. This combination approach (charcoal for co-ingestants, WBI for iron) may be optimal for mixed overdoses.

Enhanced Elimination Techniques

Urine Alkalinization

Mechanism: Increases renal elimination of weak acids by ion trapping—alkaline urine (pH 7.5-8.5) ionizes weak acids, preventing tubular reabsorption

Indications:

  • Salicylate poisoning (primary indication)
  • Chlorpropamide overdose (rare)
  • Methotrexate toxicity (in oncology settings)
  • Phenobarbital poisoning (MDAC preferred if tolerated)

Technique:

  1. Bolus: Sodium bicarbonate 1-2 mEq/kg (typically 50-100 mEq) IV over 30-60 minutes
  2. Infusion: Add 150 mEq (3 amps) sodium bicarbonate to 1 L D5W, infuse at 200-250 mL/hr
  3. Monitoring:
    • Urine pH every 2 hours (goal 7.5-8.5)
    • Serum pH, electrolytes, calcium every 2-4 hours
    • Adjust infusion to maintain target urine pH
  4. Titration: Increase or decrease infusion rate by 50 mL/hr based on urine pH

Goals:

  • Urine pH: 7.5-8.5
  • Serum pH: 7.45-7.55 (avoid severe alkalemia)
  • Urine output: 2-3 mL/kg/hr

Complications:

  • Hypokalemia: Alkalemia drives K+ intracellularly; aggressive repletion required (maintain K+ >4.0 mEq/L)
  • Volume overload: Large sodium load, monitor for pulmonary edema
  • Hypocalcemia: Alkalemia decreases ionized calcium
  • Metabolic alkalosis: Particularly if continued beyond indication

Pearl: Adequate urine alkalinization is impossible without correcting hypokalemia. The kidney will preferentially reabsorb K+ over excreting H+ when potassium-depleted, making alkalinization ineffective. Aggressively supplement potassium (20-40 mEq/L in maintenance fluids) from the start.

Salicylate Toxicity—Special Considerations:

Salicylate poisoning causes unique acid-base derangements:

  • Respiratory alkalosis: Direct stimulation of medullary respiratory center
  • Anion gap metabolic acidosis: Uncoupling oxidative phosphorylation, lactate production
  • Mixed: Both disturbances occur simultaneously

Why Alkalinization Matters:

  • Salicylate CNS toxicity correlates with brain salicylate concentration
  • Acidemia (systemic or CNS) drives salicylate into CNS (ion trapping in reverse)
  • CRITICAL: Intubation and mechanical ventilation can be fatal in salicylate toxicity if minute ventilation is not matched to the patient's compensatory hyperventilation—loss of respiratory alkalosis causes catastrophic acidemia and brain salicylate accumulation[19]

Hack: If a patient with salicylate toxicity requires intubation, match their spontaneous minute ventilation (typically 30-40 L/min). Use volume control mode with:

  • Tidal volume 8-10 mL/kg
  • Respiratory rate 30-40/min
  • Monitor end-tidal CO2 and blood gas closely
  • Consider hemodialysis as alternative to intubation when possible

Oyster: The salicylate level in chronic toxicity correlates poorly with clinical severity. Elderly patients on chronic salicylate therapy can develop life-threatening toxicity with "therapeutic" or mildly elevated levels (30-50 mg/dL). Treat based on clinical status (altered mental status, metabolic acidosis, pulmonary edema), not just the level.[20]

Hemodialysis and Extracorporeal Removal

While beyond the scope of "enhanced elimination" techniques applicable to all poisonings, recognize indications for dialysis:

Mnemonic for Dialyzable Poisons: SLIME

  • Salicylates
  • Lithium
  • Isopropanol (rarely necessary)
  • Methanol
  • Ethylene glycol

Additional Indications:

  • Valproic acid (severe toxicity)
  • Carbamazepine (refractory seizures)
  • Theophylline (level >100 mg/L)
  • Metformin (with severe lactic acidosis)

General Criteria for Dialysis:

  1. Severe toxicity despite maximal supportive care
  2. Drug is dialyzable (low molecular weight, low volume of distribution, minimal protein binding)
  3. Clinical deterioration or life-threatening complications
  4. Toxic metabolite production (methanol, ethylene glycol)

Pearl: Consult nephrology and toxicology early when considering dialysis. Many ICUs lack experience with poison-specific dialysis kinetics, and toxicology can guide duration and endpoints.


When to Consult the Poison Control Center (Hint: Always)

The Value of Toxicology Consultation

The poison control center represents an underutilized resource in critical care. In the United States, the Poison Help line (1-800-222-1222) connects to regional centers staffed 24/7 by specialists in poison information (nurses, pharmacists) with medical toxicologist backup. Services are free and confidential.

When to Call:

  • Always for unknown or poly-pharmacy overdoses
  • Any poisoning with atypical presentation
  • Unfamiliar antidote dosing or availability questions
  • Pediatric poisonings (different pharmacokinetics)
  • Occupational or environmental exposures
  • When considering unusual therapies (lipid emulsion, hemodialysis)
  • For prognostic information and disposition guidance

What They Provide:

  1. Evidence-based treatment recommendations from current literature
  2. Antidote availability and sourcing (many antidotes are not stocked in every hospital)
  3. Follow-up calls to track clinical course and adjust recommendations
  4. Documentation for medicolegal purposes
  5. Transfer assistance to toxicology centers for complex cases
  6. Access to medical toxicologists for complex consultations

Pearl: Document the poison control center case number in your medical record. This facilitates continuity if multiple providers are involved and provides medicolegal protection by demonstrating consultation with specialists.

Medical Toxicology Consultation

Beyond poison control center phone support, consider formal medical toxicology consultation for:

Absolute Indications:

  • Exotic or rare poisons (colchicine, cardiac glycosides, heavy metals)
  • Poisonings requiring specialized antidotes (digoxin immune Fab, antivenoms)
  • Extracorporeal removal considerations
  • Body packers/stuffers requiring surgical decisions
  • Prolonged toxicity requiring ICU-level toxicology expertise

Relative Indications:

  • Failure to improve with standard management
  • Diagnostic uncertainty despite workup
  • Multiple organ system involvement
  • Pregnancy with significant poisoning
  • Medicolegal complexity (assault, workplace exposure, self-harm in special populations)

Access Points:

  • Poison control center can facilitate toxicology consult
  • American College of Medical Toxicology (ACMT) maintains consultant directory
  • Many tertiary centers have toxicology services
  • Telemedicine toxicology increasingly available

Hack: Build a relationship with your regional poison control center and toxicology service before you need them urgently. Understand their capabilities, response times, and preferred communication methods. In a crisis, you'll have established channels rather than cold-calling for help.

What Information to Provide

When consulting poison control or toxicology:

Essential Information:

  1. Patient demographics: Age, weight, sex
  2. Substance(s): Name, formulation, dose, timing
  3. Route: Ingestion, inhalation, dermal, injection
  4. Intent: Intentional, unintentional, recreational
  5. Clinical status: Vital signs, GCS, pupils, skin findings
  6. Interventions: Decontamination, antidotes, supportive care given
  7. Laboratory data: Specific levels, electrolytes, acid-base status
  8. Co-morbidities: Liver/kidney disease, psychiatric history, medications

Optimize the Consultation:

  • Have pill bottles or substance containers available
  • Take photographs of substances, labels, or packaging
  • Be prepared to describe the clinical trajectory
  • Have someone available to take detailed notes
  • Ask specific questions (antidote dosing, lab monitoring, prognosis, disposition)

Oyster: Poison control centers track exposures for epidemiologic surveillance. Your call contributes to understanding emerging threats (novel psychoactive substances, contaminated drug supplies, product recalls). This public health function benefits future patients.


Putting It All Together: The Systematic Approach

The First 15 Minutes

When an undifferentiated poisoned patient arrives:

Immediate Actions (Simultaneous):

  1. Primary survey: Airway, breathing, circulation
  2. Continuous monitoring: Cardiac monitor, pulse oximetry, blood pressure
  3. IV access: At least one large-bore IV
  4. Point-of-care glucose: Hypoglycemia mimics intoxication
  5. 12-lead ECG: QRS width, QTc, conduction abnormalities
  6. Supplemental oxygen: Maintain SpO2 >94%

History (AMPLE + toxicology-specific):

  • Allergies
  • Medications (patient's, household members')
  • Past medical history (psychiatric, substance use, chronic pain)
  • Last meal (affects absorption kinetics)
  • Events (what, when, why, how much, witnesses)
  • Additional: Suicide note, pill bottles, paraphernalia, collateral from EMS/family

Physical Examination:

  • Vital signs: Include temperature (core if altered)
  • Toxidrome assessment: Systematically evaluate pupils, skin, bowel sounds, reflexes, mental status
  • Focused exam: Needle tracks, burns (caustics), trauma (fall from sympathomimetic agitation)

Initial Laboratories:

  • Basic metabolic panel: Anion gap calculation
  • Hepatic function: AST, ALT, INR (if acetaminophen concern)
  • Arterial or venous blood gas: Acid-base status, lactate
  • Serum osmolality: Calculate osmolar gap
  • Acetaminophen level: Screen everyone with intentional overdose
  • Salicylate level: Low threshold for checking
  • Ethanol level: Common co-ingestant
  • Urine pregnancy test: All females of childbearing age
  • ECG: Already done, interpret carefully

Targeted Levels (based on history/presentation):

  • Specific drugs mentioned by patient
  • Toxins suggested by toxidrome
  • Institutional "toxic screen" panels vary in utility

Pearl: The "toxic screen" or "urine drug screen" rarely changes acute management. These tests identify classes of substances (opioids, benzodiazepines, amphetamines) but:

  • Don't detect many toxins (synthetic opioids, novel psychoactive substances)
  • Don't provide quantitative levels
  • Have false positives (cross-reactivity)
  • Have false negatives (synthetic substances)
  • Results delayed (hours)

Treat the patient, not the tox screen. Clinical toxidrome recognition guides management better than laboratory testing for most poisonings.[21]

The First Hour

Stabilization:

  • Airway secured if needed (clinical assessment, not GCS alone)
  • Antidote administered if indicated:
    • Naloxone for opioid toxidrome with respiratory depression
    • Sodium bicarbonate for wide QRS from suspected TCA/sodium channel blocker
    • Consider empiric thiamine, dextrose if altered + hypoglycemia risk
  • Decontamination decision made:
    • Activated charcoal if appropriate timing and protected airway
    • Whole bowel irrigation if indicated (body packer, sustained-release, iron)
  • Enhanced elimination initiated if indicated:
    • Urine alkalinization for salicylates
    • MDAC for appropriate substances

Consultation:

  • Poison control center called (always)
  • Toxicology consultation if complex
  • Psychiatry notification if intentional self-harm (but defer formal evaluation until medically stable)
  • Nephrology if dialysis considered
  • Social work/child protective services if pediatric non-accidental poisoning suspected

Disposition Planning:

  • ICU admission criteria:
    • Ongoing hemodynamic instability
    • Respiratory support required
    • Altered mental status requiring frequent reassessment
    • Antidote infusions requiring close monitoring
    • Anticipated deterioration (delayed-onset toxins)
    • Body packer (observation for packet rupture)
  • Monitored bed criteria:
    • Symptomatic but stable
    • Substances with delayed effects (acetaminophen, ASA, iron)
    • Need for serial examinations
    • MDAC or other frequent interventions
  • Medical floor/observation:
    • Asymptomatic with non-toxic screening levels
    • Psychiatric hold after medical clearance
    • Delayed presentations with normal labs
  • Discharge:
    • Minimal exposure with completely asymptomatic course
    • Reliable patient with psychiatric follow-up arranged
    • Pediatric unintentional exposure with clear innocuous substance

Oyster: "Medical clearance" for psychiatric admission is often poorly defined. Ensure the patient is:

  • Hemodynamically stable with normal vital signs
  • Alert and oriented, back to baseline mental status
  • Cleared from medical complications (aspiration, rhabdomyolysis)
  • Acetaminophen and salicylate levels non-toxic (or appropriate NAC completed)
  • ECG normalized if previously abnormal
  • Physical exam normal

Document clearly what you're clearing and what residual risk remains (e.g., "Medically cleared from toxicology standpoint; psychiatric team to assess capacity and safety for discharge").

The First 24 Hours

Ongoing Management:

  1. Serial assessments: Vital signs, mental status, toxidrome evolution every 1-4 hours based on severity
  2. Repeat laboratories: Based on specific poison (e.g., acetaminophen at 4 hours and 24 hours, salicylate every 4 hours until declining)
  3. Supportive care optimization:
    • Fluids for rhabdomyolysis prophylaxis (sympathomimetics)
    • Benzodiazepines for agitation, seizures
    • Antiemetics for persistent vomiting
    • DVT prophylaxis if prolonged immobility
    • Aspiration precautions if altered
  4. Antidote titration: Adjust naloxone infusion, continue/discontinue NAC, monitor for deferoxamine complications
  5. Enhanced elimination assessment: Is MDAC being tolerated? Is urine alkalinization achieving target pH?
  6. Complication surveillance:
    • Aspiration pneumonitis
    • Rhabdomyolysis
    • Acute kidney injury
    • Hepatotoxicity
    • Cardiovascular complications
    • Seizures

Communication:

  • Update poison control center with clinical course
  • Coordinate with psychiatry for intentional overdoses
  • Family meetings if prolonged course expected
  • Documentation of decision-making and consultations

Clinical Pearls and Oysters: High-Yield Teaching Points

Pearls for the Poisoned Patient

  1. Supportive care trumps antidotes: The vast majority of poisoned patients survive with good airway management, hemodynamic support, and prevention of complications. Don't delay supportive care while searching for exotic antidotes.

  2. The patient is the best "tox screen": Physical examination (pupils, skin, vital signs, mental status) provides more immediately useful information than laboratory testing for guiding initial management.

  3. When you hear hoofbeats, think horses (but keep zebras in mind): Common things are common (acetaminophen, benzodiazepines, alcohol, opioids), but remain alert for rare but deadly toxins (colchicine, cardiac glycosides, toxic alcohols).

  4. The antidote to most poisonings is time: With adequate supportive care, most xenobiotics are metabolized and eliminated without specific interventions. Patience is therapeutic.

  5. Co-ingestion is the rule, not the exception: 30-50% of intentional overdoses involve multiple substances. Screen broadly, treat the clinical picture, and expect the unexpected.

  6. Treat responsive patients as though they're telling the truth, unresponsive patients as though they're not: Believe the history when the patient is alert, but when obtunded, assume the worst (bigger ingestion, more substances, earlier timing).

  7. The most dangerous time is 4-6 hours post-ingestion: Many delayed-onset toxins (acetaminophen, ASA, iron, sustained-release formulations) look benign initially. Early reassurance followed by unexpected deterioration is the pattern.

  8. QRS duration is the most important ECG parameter in overdose: Wide QRS (>100 ms) suggests sodium channel blockade (TCAs, cocaine, diphenhydramine, propranolol, quinidine, local anesthetics) and mandates aggressive treatment with sodium bicarbonate and cardiac monitoring.

  9. Agitation kills: Sympathomimetic toxicity causes death through hyperthermia, rhabdomyolysis, and cardiovascular collapse—all preventable with adequate sedation. Titrate benzodiazepines aggressively.

  10. The pupils don't lie (usually): Pupil examination is remarkably reliable for toxidrome identification, but remember: miosis doesn't always mean opioids (clonidine, pontine stroke, organophosphates), and mydriasis doesn't always mean anticholinergic (sympathomimetics, serotonin syndrome).

Oysters (Dangerous Pitfalls)

  1. The "stable" body packer is never stable: Cocaine or heroin packets in the GI tract represent ticking time bombs. Packet rupture causes massive, often lethal toxicity. Admit to ICU, consult surgery, consider WBI, have antidotes ready.

  2. Intubating the salicylate patient without matching their minute ventilation is potentially fatal: Loss of compensatory hyperventilation causes precipitous acidemia and brain salicylate accumulation. Match their pre-intubation ventilation (often 30-40 L/min) or consider hemodialysis as an alternative to intubation.

  3. Beta-blocker and calcium channel blocker toxicity can masquerade as septic shock: Profound vasodilatory shock with relative bradycardia—don't miss this diagnosis by assuming all shock is septic. History is critical; treatment differs dramatically (high-dose insulin, calcium, glucagon, lipid emulsion vs. antibiotics).

  4. Hypoglycemia is not just for diabetics: Ethanol, beta-blockers, sulfonylureas, salicylates, and insulin can all cause profound hypoglycemia. Check glucose in every altered patient, even without diabetes history.

  5. Serotonin syndrome can kill quickly: This is not a benign condition. Hyperthermia >41°C, rigidity, rhabdomyolysis, DIC, and multi-organ failure develop rapidly. Aggressive cooling, benzodiazepines, cyproheptadine, and sometimes paralysis/intubation are required. Stop all serotonergic agents.

  6. Delayed acetaminophen hepatotoxicity occurs despite normal initial presentation: The patient who presents 2 hours post-ingestion with no symptoms still needs a 4-hour level and possible NAC. Hepatotoxicity peaks at 3-4 days, long after the patient feels fine.

  7. Chronic salicylate toxicity in the elderly is more dangerous than acute overdose: Elderly patients develop toxicity at lower levels, present with non-specific symptoms (confusion, tachypnea), and have higher mortality. Always check ASA level in elderly patients with unexplained altered mental status or acid-base disturbances.

  8. Propofol infusion syndrome looks like toxic ingestion: Profound lactic acidosis, rhabdomyolysis, cardiovascular collapse, and renal failure—but the "poison" is iatrogenic. Consider this in ICU patients on prolonged propofol infusions, especially children or patients receiving >4 mg/kg/hr for >48 hours.

  9. Lipid emulsion therapy is not benign: While potentially life-saving for lipophilic drug overdose (local anesthetics, calcium channel blockers, beta-blockers, TCAs), lipid emulsion causes pancreatitis, fat embolism, and interference with laboratory testing. Consult toxicology before administration in most cases (except local anesthetic systemic toxicity, where it's first-line).[22]

  10. The "hangover" that won't quit might be toxic alcohol ingestion: Persistent altered mental status, worsening acidosis, and osmolar gap hours after suspected ethanol ingestion suggest methanol or ethylene glycol. These require fomepizole and hemodialysis, not just supportive care.


Conclusion

The management of the poisoned patient remains one of the most challenging and intellectually stimulating aspects of critical care medicine. While specific antidotes and targeted therapies capture attention, the foundation of successful outcomes rests on meticulous supportive care, systematic clinical assessment, and early consultation with toxicology experts.

The approach outlined in this review—beginning with the primary survey, proceeding through toxidrome recognition, judiciously applying antidotes, considering enhanced elimination when appropriate, and always consulting poison control—provides a framework applicable to virtually any poisoning scenario. As the landscape of toxic exposures evolves with novel psychoactive substances, designer drugs, and emerging pharmaceuticals, this systematic approach remains constant.

Remember: treat the patient, not the poison. Excellent airway management, hemodynamic support, seizure control, and prevention of complications will save more lives than memorizing every antidote. When in doubt, call poison control—their expertise is available 24/7, free of charge, and can make the difference between good and excellent care.

The poisoned patient challenges us to be both systematic and creative, evidence-based yet pragmatic, and above all, to remember that behind every toxidrome is a person whose life may depend on our ability to synthesize disparate clues into coherent action.


References

  1. Mowry JB, Spyker DA, Brooks DE, et al. 2015 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 33rd Annual Report. Clin Toxicol (Phila). 2016;54(10):924-1109.

  2. Zimmerman JL. Poisonings and overdoses in the intensive care unit: general and specific management issues. Crit Care Med. 2003;31(12):2794-2801.

  3. Mokhlesi B, Leikin JB, Murray P, Corbridge TC. Adult toxicology in critical care: Part I: general approach to the intoxicated patient. Chest. 2003;123(2):577-592.

  4. Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet. 2008;371(9612):597-607.

  5. Kraut JA, Kurtz I. Toxic alcohol ingestions: clinical features, diagnosis, and management. Clin J Am Soc Nephrol. 2008;3(1):208-225.

  6. Manini AF, Nelson LS, Skolnick AH, et al. Electrocardiographic predictors of adverse cardiovascular events in suspected poisoning. J Med Toxicol. 2010;6(1):106-115.

  7. Somerville NJ, O'Donnell J, Gladden RM, et al. Characteristics of Fentanyl Overdose — Massachusetts, 2014–2016. MMWR Morb Mortal Wkly Rep. 2017;66(14):382-386.

  8. Richards JR, Albertson TE, Derlet RW, et al. Treatment of toxicity from amphetamines, related derivatives, and analogues: A systematic clinical review. Drug Alcohol Depend. 2015;150:1-13.

  9. Kerr GW, McGuffie AC, Wilkie S. Tricyclic antidepressant overdose: a review. Emerg Med J. 2001;18(4):236-241.

  10. Peter JV, Sudarsan TI, Moran JL. Clinical features of organophosphate poisoning: A review of different classification systems and approaches. Indian J Crit Care Med. 2014;18(11):735-745.

  11. Mason PE, Kerns WP 2nd. Gamma hydroxybutyric acid (GHB) intoxication. Acad Emerg Med. 2002;9(7):730-739.

  12. Gowing L, Ali R, White JM. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2017;2(2):CD002025.

  13. Weinbroum AA, Flaishon R, Sorkine P, Szold O, Rudick V. A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose. Drug Saf. 1997;17(3):181-196.

  14. Tenenbein M. Benefits of parenteral deferoxamine for acute iron poisoning. J Toxicol Clin Toxicol. 1996;34(5):485-489.

  15. Bateman DN, Dear JW, Thanacoody HK, et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet. 2014;383(9918):697-704.

  16. Bunchorntavakul C, Reddy KR. Acetaminophen (APAP or N-Acetyl-p-Aminophenol) and Acute Liver Failure. Clin Liver Dis. 2018;22(2):325-346.

  17. Position paper: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol. 1997;35(7):721-741.

  18. Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol. 1999;37(6):731-751.

  19. Stolbach AI, Hoffman RS, Nelson LS. Mechanical ventilation was associated with acidemia in a case series of salicylate-poisoned patients. Acad Emerg Med. 2008;15(9):866-869.

  20. Juurlink DN, Gosselin S, Kielstein JT, et al. Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Ann Emerg Med. 2015;66(2):165-181.

  21. Mokhlesi B, Leiken JB, Murray P, Corbridge TC. Adult toxicology in critical care: Part II: specific poisonings. Chest. 2003;123(3):897-922.

  22. American College of Medical Toxicology. ACMT Position Statement: Guidance for the Use of Intravenous Lipid Emulsion. J Med Toxicol. 2017;13(1):124-125.


Suggested Further Reading

  • Goldfrank LR, Hoffman RS, Howland MA, et al. Goldfrank's Toxicologic Emergencies, 11th ed. New York: McGraw-Hill; 2019.

  • Nelson LS, Howland MA, Lewin NA, et al. Goldfrank's Toxicologic Emergencies, 11th ed. New York: McGraw-Hill Education; 2019.

  • Olson KR, ed. Poisoning & Drug Overdose, 7th ed. New York: McGraw-Hill Education; 2018.

  • Brent J, Wallace KL, Burkhart KK, et al. Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient, 2nd ed. Cham: Springer; 2017.


Author Disclosure: The author reports no conflicts of interest relevant to this manuscript.

Correspondence: For questions regarding this review, contact your local poison control center at 1-800-222-1222 (United States).

Thursday, October 2, 2025

The Confusing World of Corticosteroids: A Practical Prescriber's Guide

 

The Confusing World of Corticosteroids: A Practical Prescriber's Guide

Dr Neeraj Manikath , claude.ai

Abstract

Corticosteroids remain among the most prescribed medications in critical care and general medicine, yet their use is fraught with complexity and potential complications. This comprehensive review addresses practical challenges in corticosteroid prescribing, including dose equivalencies, withdrawal risks, tapering strategies, chronic side effect management, and stress dosing protocols. Written for postgraduate trainees in critical care and internal medicine, this guide synthesizes evidence-based recommendations with clinical pearls to optimize patient outcomes while minimizing adverse effects.

Keywords: Corticosteroids, adrenal insufficiency, HPA axis suppression, stress dosing, steroid tapering, critical care


Introduction

Corticosteroids are indispensable therapeutic agents with profound anti-inflammatory and immunosuppressive properties. Despite their ubiquity in clinical practice, prescribing corticosteroids appropriately requires nuanced understanding of pharmacokinetics, equivalency dosing, hypothalamic-pituitary-adrenal (HPA) axis physiology, and potential complications. Errors in dosing conversions, abrupt discontinuation, inadequate stress dosing, or failure to mitigate chronic side effects can lead to significant morbidity and mortality.

This review provides a practical framework for safe and effective corticosteroid prescribing in hospitalized and ambulatory patients, with emphasis on high-risk scenarios encountered in critical care settings.


1. Equivalent Dosing: Converting Between Prednisone, Methylprednisolone, and Dexamethasone

The Foundation: Understanding Potency and Duration

Corticosteroids differ significantly in glucocorticoid potency, mineralocorticoid activity, and biological half-life. These pharmacological distinctions are crucial for appropriate dosing conversions.

Table 1: Comparative Corticosteroid Properties

Agent Equivalent Dose (mg) Glucocorticoid Potency Mineralocorticoid Potency Biological Half-Life Duration of Action
Hydrocortisone 20 1 1 8-12 hours Short (8-12h)
Prednisone/Prednisolone 5 4 0.8 12-36 hours Intermediate (12-36h)
Methylprednisolone 4 5 0.5 12-36 hours Intermediate (12-36h)
Dexamethasone 0.75 25-30 0 36-72 hours Long (36-72h)
Fludrocortisone N/A (mineralocorticoid) 10 125 18-36 hours N/A

Practical Conversion Formulas

Key Clinical Conversions:

  1. Prednisone to Methylprednisolone: Multiply by 0.8

    • 40 mg prednisone = 32 mg methylprednisolone
  2. Prednisone to Dexamethasone: Divide by 6.67 (approximately 7)

    • 40 mg prednisone ≈ 6 mg dexamethasone
  3. Methylprednisolone to Dexamethasone: Divide by 5.33 (approximately 5)

    • 40 mg methylprednisolone ≈ 7.5 mg dexamethasone
  4. Hydrocortisone to Prednisone: Divide by 4

    • 100 mg hydrocortisone = 25 mg prednisone

Clinical Pearls 💎

Pearl 1: The Dexamethasone Dilemma Dexamethasone's prolonged HPA axis suppression (36-54 hours) makes it unsuitable for every-other-day regimens and complicates transition to physiologic replacement. Use short-acting agents (hydrocortisone) or intermediate-acting agents (prednisone) when tapering is anticipated.

Pearl 2: Mineralocorticoid Considerations When converting from hydrocortisone (significant mineralocorticoid activity) to prednisone or dexamethasone (minimal mineralocorticoid activity), consider adding fludrocortisone 0.05-0.1 mg daily for patients with adrenal insufficiency to prevent salt-wasting and hypotension.

Pearl 3: The Methylprednisolone IV Advantage Methylprednisolone has superior bioavailability when given intravenously (88% vs. 82% for hydrocortisone) and causes less mineralocorticoid-mediated sodium retention—ideal for pulse-dose therapy in conditions like severe COPD exacerbations or acute spinal cord injury.

Oyster Alert 🦪

Oyster 1: Prednisone vs. Prednisolone Prednisone requires hepatic conversion to active prednisolone. In severe hepatic dysfunction, prednisolone should be prescribed directly, or alternative agents used. This distinction is often overlooked in cirrhotic patients.

Oyster 2: The Bioavailability Trap Oral bioavailability varies: prednisone (80%), methylprednisolone (90%), dexamethasone (80%). When converting from IV to PO, some clinicians erroneously increase doses. The conversions in Table 1 already account for bioavailability differences for standard preparations.

Clinical Hack 🔧

Quick Mental Math for Dexamethasone: Divide prednisone dose by 7 for rapid approximation. For example, 60 mg prednisone ≈ 8-9 mg dexamethasone. This "divide by 7" rule works reasonably well in most clinical scenarios and is easier to remember than 6.67.


2. The Perils of Sudden Withdrawal: HPA Axis Suppression and Adrenal Insufficiency

Understanding HPA Axis Physiology

The HPA axis represents a delicate neuroendocrine feedback system. Exogenous glucocorticoids suppress corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secretion, leading to adrenal atrophy. Recovery of the HPA axis after cessation of exogenous steroids can take 6-12 months or longer.

Risk Factors for HPA Axis Suppression

High-Risk Scenarios:

  • Duration: >3 weeks of supraphysiologic doses (>5 mg/day prednisone equivalent)
  • Dose: Any dose >20 mg/day prednisone for >2 weeks
  • Timing: Evening dosing (disrupts circadian cortisol rhythm more than morning dosing)
  • Potency: Long-acting agents (dexamethasone) suppress HPA axis more profoundly
  • Route: Topical, inhaled, or intra-articular steroids can cause HPA suppression with prolonged use

Clinical Manifestations of Acute Adrenal Insufficiency

Acute adrenal crisis is a life-threatening emergency with mortality up to 6% even with treatment:

Classic Presentation:

  • Hypotension refractory to fluids and vasopressors
  • Fever, altered mental status
  • Nausea, vomiting, abdominal pain
  • Hyponatremia, hyperkalemia (in primary adrenal insufficiency)
  • Hypoglycemia
  • Eosinophilia

Atypical Presentations in the ICU:

  • Unexplained hypotension after routine procedures
  • Prolonged vasopressor dependence in septic shock
  • "Failure to wean" from mechanical ventilation
  • Hypoglycemia in non-diabetic patients

Diagnosis and Management

Diagnostic Approach:

  1. Random cortisol level: <3 μg/dL strongly suggests adrenal insufficiency; >15 μg/dL makes it unlikely
  2. ACTH stimulation test: Can be performed but should NOT delay treatment
  3. Threshold for empiric treatment should be LOW in suspected cases

Acute Management Protocol:

  1. Hydrocortisone 100 mg IV bolus immediately (do NOT wait for test results)
  2. Aggressive fluid resuscitation: 1-2L normal saline bolus
  3. Continued hydrocortisone: 50-100 mg IV every 6-8 hours or 200 mg/24h continuous infusion
  4. Identify and treat precipitating factors: Infection, trauma, surgery, rapid steroid taper
  5. Transition to oral therapy: Once stable, switch to oral hydrocortisone 15-25 mg/day in divided doses

Clinical Pearls 💎

Pearl 4: The "Cushingoid" Patient Can Still Have Adrenal Insufficiency Physical signs of Cushing's syndrome (moon facies, striae, buffalo hump) indicate chronic steroid exposure but do NOT exclude HPA axis suppression. These patients are at HIGH risk for adrenal crisis if steroids are abruptly discontinued.

Pearl 5: Infection as a Trigger In patients on chronic steroids, any acute illness (infection, trauma, surgery) can precipitate adrenal crisis. Maintain high index of suspicion in chronic steroid users with unexplained shock.

Pearl 6: The Dexamethasone Diagnostic Window If adrenal insufficiency is suspected but diagnosis uncertain, give dexamethasone 4 mg IV (does NOT interfere with cortisol assay) while performing ACTH stimulation test. This provides glucocorticoid coverage without compromising diagnostic accuracy.

Oyster Alert 🦪

Oyster 3: Secondary vs. Primary Adrenal Insufficiency Steroid-induced HPA suppression causes SECONDARY adrenal insufficiency (low ACTH). Unlike primary adrenal insufficiency (Addison's disease), mineralocorticoid function is preserved via the renin-angiotensin system. Therefore, hyperkalemia is UNCOMMON. Hyponatremia may still occur via vasopressin-mediated mechanisms.

Oyster 4: Inhaled Steroids Are Not Innocent High-dose inhaled corticosteroids (>1000 μg/day fluticasone equivalent) can suppress the HPA axis, especially in children and when combined with oral steroids. Consider HPA suppression even in patients not on oral steroids.

Clinical Hack 🔧

The "Steroid Passport" System: Implement a standardized alert in the electronic medical record for all patients receiving >20 mg prednisone equivalent for >2 weeks. Include automatic alerts for stress-dosing protocols during hospitalizations, procedures, or illness. Consider providing patients with a "steroid card" documenting their regimen.


3. Tapering Strategies: When and How to Taper Safely

When to Taper vs. Abrupt Discontinuation

Safe for Abrupt Discontinuation:

  • <3 weeks of therapy at any dose
  • Any duration of physiologic replacement dosing (≤5 mg prednisone daily)
  • Alternate-day short-acting regimens of <10 days

Requires Tapering:

  • 3 weeks of supraphysiologic dosing

  • Any duration if Cushingoid features present
  • Uncertain duration or patient non-adherent to previous courses

Evidence-Based Tapering Approaches

Multiple tapering strategies exist, but no single approach has been proven superior. The key principles are: gradual dose reduction, monitoring for adrenal insufficiency, and individualization.

Standard Tapering Protocol:

  1. Initial Phase (Rapid Taper): If >40 mg/day prednisone, reduce by 5-10 mg weekly until reaching 20 mg/day
  2. Intermediate Phase (Moderate Taper): From 20 mg to 10 mg, reduce by 2.5-5 mg weekly
  3. Final Phase (Slow Taper): Below 10 mg/day (approaching physiologic doses):
    • Reduce by 1 mg every 2-4 weeks OR
    • Reduce by 2.5 mg every 2-4 weeks until 5 mg daily
  4. Physiologic Replacement Phase: At 5 mg/day, some clinicians:
    • Continue 5 mg daily for 4-8 weeks to allow HPA axis recovery, then discontinue OR
    • Taper to 2.5 mg for 2-4 weeks, then discontinue OR
    • Perform ACTH stimulation testing before complete cessation

Alternative: Hybrid Approach

  • Transition to hydrocortisone 15-20 mg/day (mimics physiologic cortisol secretion) given as 10 mg AM, 5 mg afternoon
  • Continue for 1-2 months, then taper hydrocortisone by 2.5 mg every 2 weeks
  • This approach may facilitate HPA axis recovery by allowing physiologic diurnal variation

Disease-Specific Considerations

Autoimmune Conditions:

  • Monitor disease activity markers (ESR, CRP, disease-specific symptoms)
  • Be prepared to slow taper or increase dose temporarily if flare occurs
  • Consider steroid-sparing immunosuppressive agents early

Severe Asthma/COPD:

  • Optimize inhaled corticosteroids and bronchodilators before tapering systemic steroids
  • Monitor FEV1 and symptoms closely
  • Consider slower taper in frequent exacerbators

Polymyalgia Rheumatica/Giant Cell Arteritis:

  • Classic prolonged taper (12-24 months typical)
  • Initial dose 40-60 mg prednisone; reduce by 10 mg every 2 weeks to 20 mg
  • Then 2.5 mg every 2-4 weeks with close symptom monitoring
  • ESR/CRP surveillance for disease recurrence

Monitoring During Tapering

Clinical Assessment:

  • Fatigue, weakness, anorexia, weight loss (adrenal insufficiency symptoms)
  • Disease-specific symptoms (joint pain, shortness of breath, rash, etc.)
  • Vital signs: postural hypotension suggests adrenal insufficiency

Laboratory Monitoring:

  • Morning cortisol level (drawn before AM steroid dose) when reaching 5 mg prednisone or equivalent
    • 10 μg/dL: HPA axis recovery likely adequate

    • 3-10 μg/dL: Indeterminate; may need stimulation test or continued slow taper
    • <3 μg/dL: HPA axis suppressed; continue replacement
  • ACTH stimulation test (if available and indicated): Peak cortisol >18-20 μg/dL indicates adequate adrenal reserve

Clinical Pearls 💎

Pearl 7: The Morning Cortisol Timing Trick When checking morning cortisol to assess HPA axis recovery, draw labs at 8 AM BEFORE the morning steroid dose (ideally after holding steroids for 24 hours). Cortisol levels peak physiologically at 8 AM; levels at other times are less interpretable.

Pearl 8: Symptoms Lag Behind Labs Patients may experience fatigue and malaise during tapering even with adequate cortisol levels. This may represent a "steroid withdrawal syndrome" (distinct from adrenal insufficiency). Consider slower taper, patient education, and symptomatic support, but don't abandon the taper without evidence of true adrenal insufficiency.

Pearl 9: The Alternate-Day Strategy For chronic steroid-dependent conditions, consider alternate-day therapy with short-acting agents (prednisone, prednisolone) once daily dose is <15 mg. Give entire dose on alternate mornings. This minimizes HPA suppression while maintaining therapeutic effect for some conditions. Does NOT work with long-acting dexamethasone.

Oyster Alert 🦪

Oyster 5: The "Stuck at 5 mg" Phenomenon Many patients and physicians get "stuck" at 5 mg prednisone for years due to fear of adrenal crisis or symptom recurrence. However, 5 mg prednisone is still supraphysiologic (physiologic production = 15-25 mg hydrocortisone ≈ 4 mg prednisone), leading to cumulative steroid toxicity. Don't abandon the taper—but go slowly below 5 mg.

Oyster 6: Over-reliance on Cortisol Levels A low morning cortisol during taper doesn't always require stopping the taper or increasing the dose. If patient is asymptomatic and not facing physiologic stress, many clinicians continue slow taper with close monitoring. The ultimate goal is discontinuation.

Clinical Hack 🔧

Microdose Tapering for Difficult Cases: For patients who repeatedly fail conventional tapers, consider 0.5-1 mg reductions every 4-6 weeks. Use liquid prednisone formulations or compound customized doses. Though slower, this ultra-gradual approach has high success rates in steroid-dependent patients.


4. Managing Chronic Side Effects: Osteoporosis, Hyperglycemia, and Cataracts

Chronic corticosteroid therapy causes predictable, dose-dependent, cumulative adverse effects. Preventive strategies must be implemented early and monitored throughout treatment.

Glucocorticoid-Induced Osteoporosis (GIOP)

GIOP is the most common cause of secondary osteoporosis. Fracture risk increases within 3-6 months of initiating therapy, even before significant bone density decline.

Pathophysiology:

  • Decreased osteoblast function and increased osteoclast activity
  • Impaired intestinal calcium absorption and increased renal calcium excretion
  • Suppressed sex hormone production
  • Direct myopathic effects leading to falls

Prevention and Treatment Guidelines:

All Patients on ≥2.5 mg Prednisone Daily for ≥3 Months:

  1. Calcium supplementation: 1200-1500 mg/day (dietary + supplemental)
  2. Vitamin D: 800-1000 IU daily (target 25-OH vitamin D >30 ng/mL)
  3. Lifestyle modifications: Weight-bearing exercise, smoking cessation, fall prevention
  4. FRAX score calculation: Assess 10-year fracture risk

High-Risk Patients Requiring Bisphosphonate Therapy:

  • Postmenopausal women or men >50 years on ≥7.5 mg prednisone equivalent daily
  • Any patient with prior fragility fracture
  • T-score ≤-2.5 at spine or hip
  • T-score -1.0 to -2.5 with FRAX 10-year major osteoporotic fracture risk >20% or hip fracture risk >3%

Preferred Agents:

  • Alendronate 70 mg weekly or risedronate 35 mg weekly (first-line)
  • Zoledronic acid 5 mg IV annually (if poor oral tolerance or adherence)
  • Denosumab 60 mg SC every 6 months (if contraindications to bisphosphonates)
  • Teriparatide (PTH 1-34) (for severe osteoporosis or multiple fractures; anabolic agent)

Monitoring:

  • Baseline DXA scan before or within 6 months of starting chronic steroids
  • Repeat DXA every 1-2 years (more frequently if high risk or declining BMD)
  • Annual vertebral fracture assessment (VFA) or lateral spine X-rays in high-risk patients

Steroid-Induced Hyperglycemia and Diabetes

Corticosteroids cause insulin resistance and increase hepatic gluconeogenesis. Hyperglycemia pattern is typically characterized by post-prandial elevation with relatively preserved fasting glucose initially.

Risk Stratification:

  • Highest risk: Pre-existing diabetes, prediabetes, obesity, family history
  • Dose-dependent: Risk increases significantly at >20 mg/day prednisone equivalent
  • Time-dependent: Hyperglycemia typically emerges within days of starting therapy

Screening and Monitoring:

  • Pre-treatment: Hemoglobin A1c and fasting glucose in all patients
  • During therapy:
    • Non-diabetics on high-dose steroids: Check fasting glucose or random glucose 1-2 times weekly initially
    • Known diabetics: Intensify glucose monitoring; expect insulin requirement increases of 50-200%
    • Consider continuous glucose monitoring (CGM) in high-risk inpatients

Management Strategies:

Inpatient Hyperglycemia:

  1. Insulin therapy is FIRST-LINE for significant steroid-induced hyperglycemia
    • NPH insulin pattern matches prednisone-induced hyperglycemia (afternoon peak)
    • Typical regimen: NPH 0.1-0.2 units/kg with breakfast (for AM prednisone)
    • Add rapid-acting insulin for meal coverage as needed
    • For dexamethasone (long-acting): Consider basal insulin (glargine/degludec) or split NPH dosing
  2. Adjust insulin doses proactively with steroid dose changes (increase insulin proportionally)

Outpatient Management:

  • Metformin: Continue if already prescribed; limited efficacy as monotherapy for SIDM
  • DPP-4 inhibitors: Moderate efficacy; well-tolerated
  • GLP-1 agonists: Increasingly used; address both hyperglycemia and weight gain
  • Insulin: Often necessary for adequate control; educate patients on temporary need
  • Target HbA1c: <8% reasonable for most patients on chronic steroids (balance control vs. hypoglycemia risk)

Special Consideration: "Steroid Diabetes" Resolution Steroid-induced hyperglycemia typically resolves or improves significantly after steroid discontinuation. Anticipate reducing or stopping diabetes medications during steroid taper. Monitor for hypoglycemia.

Ocular Complications: Cataracts and Glaucoma

Posterior Subcapsular Cataracts (PSC):

  • Occur in 10-30% of patients on chronic steroids (dose and duration-dependent)
  • Risk increases significantly with >10 mg/day prednisone for >1 year
  • May be irreversible even after steroid cessation
  • Screening: Annual ophthalmologic examination for patients on chronic steroids

Steroid-Induced Glaucoma:

  • Elevated intraocular pressure in 30-40% of patients (genetic susceptibility)
  • Can occur with topical, inhaled, or systemic steroids
  • Usually reversible with steroid discontinuation but may cause permanent vision loss if undetected
  • Screening: Baseline and periodic intraocular pressure measurements

Prevention: No effective prevention for cataracts; early detection is key. For glaucoma, consider prophylactic IOP-lowering drops in high-risk patients or those on long-term therapy.

Other Important Chronic Side Effects

Cardiovascular:

  • Hypertension (monitor BP at every visit; treat per guidelines)
  • Dyslipidemia (screen lipids; consider statin therapy)
  • Increased cardiovascular events (minimize dose and duration)

Infection Risk:

  • Screen for latent TB before starting long-term therapy (>1 month of ≥15 mg/day)
  • Pneumocystis jirovecii pneumonia (PCP) prophylaxis if ≥20 mg prednisone for >1 month + other immunosuppression
  • Consider strongyloides screening in endemic areas

Psychiatric:

  • Insomnia, mood changes, psychosis (5-10% of patients)
  • Dose-related; risk highest with >40 mg/day prednisone
  • Usually resolves with dose reduction; may require antipsychotics for severe cases

Dermatologic:

  • Skin thinning, easy bruising, striae, poor wound healing
  • No effective prevention; minimize trauma

Gastrointestinal:

  • Controversial association with PUD (may be confounded by NSAID use)
  • PPI generally NOT required unless concurrent NSAIDs or PUD history

Clinical Pearls 💎

Pearl 10: Bisphosphonates Should Be Preventive, Not Reactive Unlike postmenopausal osteoporosis where treatment is often initiated after bone loss occurs, GIOP prevention with bisphosphonates should start early—ideally when initiating chronic steroids in high-risk patients. Fracture risk increases BEFORE significant BMD decline.

Pearl 11: The Steroid-Hyperglycemia Pattern Prednisone taken in the morning causes afternoon and evening hyperglycemia with relative sparing of fasting glucose. Tailor insulin regimens accordingly (NPH with breakfast works well). Dexamethasone causes more prolonged, sustained hyperglycemia.

Pearl 12: GLP-1 Agonists as Dual-Purpose Agents GLP-1 receptor agonists (semaglutide, dulaglutide) address two major steroid side effects: hyperglycemia AND weight gain. Consider in appropriate patients on long-term steroids, particularly those with obesity or metabolic syndrome.

Oyster Alert 🦪

Oyster 7: The PPI Overuse Problem Routine PPI prophylaxis in patients on steroids alone (without NSAIDs) lacks evidence and contributes to polypharmacy. PPIs themselves have risks (C. difficile infection, fractures, micronutrient deficiencies). Reserve for patients with concurrent NSAID use or PUD history.

Oyster 8: The "My Patient Needs Calcium and Vitamin D" Illusion Calcium and vitamin D alone are INSUFFICIENT to prevent GIOP in high-risk patients. They are necessary but not sufficient. Many clinicians stop at calcium/vitamin D supplementation without prescribing indicated bisphosphonate therapy, leaving patients unprotected.

Clinical Hack 🔧

Steroid Side Effect Bundle Order Set: Create a standardized order set for chronic steroid prescriptions that automatically includes:

  • Calcium 1200 mg + Vitamin D 800 IU daily
  • PPI only if concurrent NSAID or PUD history
  • Bisphosphonate prescription pending DXA results (for high-risk patients)
  • Ophthalmology referral for annual eye exam
  • Glucose monitoring orders
  • Patient education handout on steroid side effects and warning signs

This "bundle" approach dramatically improves adherence to preventive care guidelines.


5. Stress Dosing for the Hospitalized Patient on Chronic Steroids

Physiologic Principles

Normal adrenal cortisol production is 15-25 mg/day (cortisol equivalent). During physiologic stress (surgery, infection, trauma), cortisol production increases 2-10 fold (up to 200-300 mg/day cortisol equivalent in severe stress). Patients with HPA axis suppression cannot mount this response, risking cardiovascular collapse.

Risk Stratification for HPA Axis Suppression

High Risk (Assume HPA Suppression):

  • Current use of ≥20 mg/day prednisone for ≥3 weeks
  • Cushingoid features (regardless of dose or duration)
  • Any supraphysiologic dose (>5 mg prednisone) for >3 months
  • Stopped steroids within past 12 months (after prolonged use)

Intermediate Risk (Consider Testing or Empiric Coverage):

  • 10-20 mg/day prednisone for 2-3 weeks
  • Lower doses for >3 months without Cushingoid features
  • Multiple short courses in past year

Low Risk (HPA Axis Likely Intact):

  • <10 mg/day prednisone for <3 weeks
  • Physiologic replacement doses only (≤5 mg/day)
  • Stopped steroids >12 months ago (after short-term use)

Stress Dosing Protocols by Stress Level

Minor Stress (e.g., Dental Procedures, Simple Diagnostic Tests):

  • Continue usual dose; no additional coverage needed
  • Examples: Dental cleaning, endoscopy without sedation, minor dermatologic procedures

Moderate Stress (e.g., Moderate Surgery, Severe Illness):

  • Protocol: Hydrocortisone 50 mg IV before procedure, then 25 mg IV q8h for 24-48 hours
  • Alternative: Continue home dose + supplemental hydrocortisone 50 mg IV/PO on day of stress
  • Examples: Colonoscopy with sedation, pneumonia, cholecystectomy, joint arthroplasty, severe cellulitis

Major Stress (e.g., Major Surgery, Critical Illness, Septic Shock):

  • Protocol: Hydrocortisone 100 mg IV bolus, then 50 mg IV q6-8h or 200 mg/24h continuous infusion
  • Taper over 2-3 days as stress resolves: 100 mg → 50 mg → 25 mg q8h → home dose
  • Examples: Cardiac surgery, major abdominal surgery, septic shock, ARDS, severe trauma, ICU admission with hemodynamic instability

Practical Implementation

Preoperative Assessment:

  1. Identify all patients on steroids (including recent discontinuation)
  2. Stratify risk of HPA suppression
  3. Coordinate with surgery and anesthesia teams
  4. Order stress-dose hydrocortisone to be available immediately

Intraoperative/Procedure:

  • Administer hydrocortisone before induction (ideally 30-60 minutes prior)
  • Continue intraoperative dosing per protocol
  • Monitor blood pressure closely; unexplained hypotension may indicate inadequate dosing

Postoperative/Post-Event:

  • Continue stress dosing for 24-48 hours (moderate stress) or until hemodynamically stable (major stress)
  • Taper back to home regimen over 1-3 days
  • Do NOT abruptly stop stress dosing and return to physiologic doses

Special Populations and Scenarios

Septic Shock:

  • Consider "low-dose hydrocortisone" for refractory septic shock: 200 mg/24h continuous infusion or 50 mg IV q6h
  • This is BOTH stress-dose coverage AND adjunctive sepsis treatment
  • Continue for 3-7 days, then taper gradually

Trauma and Burns:

  • Assume HPA axis suppression in chronic steroid users with major trauma
  • Use high-dose stress coverage (hydrocortisone 100 mg q8h or 300 mg/24h infusion)
  • Prolonged coverage may be necessary (days to weeks)

Unrecognized Adrenal Insufficiency:

  • If unexplained shock in any patient (steroid use unknown), consider empiric hydrocortisone 100 mg IV
  • "When in doubt, treat" — risk-benefit strongly favors treatment
  • Send cortisol and ACTH levels BEFORE first dose (but don't delay treatment)

Oral to IV Conversion During NPO Status:

  • If patient NPO: Convert home oral dose to IV equivalent (use Table 1)
  • Example: Home dose prednisone 10 mg PO daily → hydrocortisone 40 mg IV daily (given as 20 mg IV q12h or 10 mg IV q6h) + stress-dose supplementation as indicated

Clinical Pearls 💎

Pearl 13: Don't Forget the Dexamethasone Caveat If adrenal insufficiency suspected, dexamethasone 4 mg IV can be given BEFORE diagnostic testing (ACTH stimulation) without interfering with cortisol assay (dexamethasone doesn't cross-react with cortisol immunoassay). Switch to hydrocortisone after testing.

Pearl 14: The "Double Coverage" Myth Some clinicians worry about giving stress-dose steroids to patients already on chronic steroids, fearing toxicity. However, even patients on 60 mg prednisone daily require ADDITIONAL hydrocortisone during major stress because:

  1. The HPA axis is suppressed and cannot respond to stress
  2. Stress cortisol requirements (200-300 mg) exceed chronic oral doses
  3. Short-term high-dose steroids (2-3 days) rarely cause significant harm

Pearl 15: The Taper After Stress After major stress, don't abruptly return to chronic maintenance dose. Taper stress-dose steroids over 2-3 days (e.g., 100 mg q8h → 50 mg q8h → 25 mg q8h → resume home dose) to mimic physiologic cortisol recovery and prevent rebound hypotension.

Oyster Alert 🦪

Oyster 9: Inhaled/Topical Steroid Users Need Stress Dosing Too High-dose inhaled corticosteroids (>1000 μg/day fluticasone or equivalent) or potent topical steroids (especially clobetasol on large surface areas) can suppress the HPA axis. Don't dismiss the need for stress dosing in these patients—obtain detailed medication history including all steroid formulations.

Oyster 10: The Etomidate Problem Etomidate, commonly used for rapid sequence intubation, inhibits 11β-hydroxylase and causes temporary adrenal insufficiency lasting 24-48 hours. In patients with pre-existing HPA suppression, a single dose of etomidate can precipitate profound adrenal crisis. Consider alternative induction agents (ketamine, propofol) or provide stress-dose steroids.

Clinical Hack 🔧

The "Rule of 100s" for Stress Dosing: For quick bedside decision-making:

  • Moderate stress: ~100 mg hydrocortisone total per day (e.g., 50 mg IV × 1, then 25 mg q8h)
  • Major stress: ~100 mg hydrocortisone every 8 hours (or 300 mg/24h infusion)
  • Duration: 100 mg protocol for 2-3 days, then taper

This oversimplified rule works for most clinical scenarios and is easy to remember under pressure.


Conclusion

Corticosteroids remain powerful therapeutic tools, but their use demands meticulous attention to dosing equivalencies, withdrawal risks, chronic complications, and stress-dosing requirements. Key principles for safe prescribing include:

  1. Master the conversions: Understanding glucocorticoid potency differences prevents dosing errors during transitions between agents
  2. Respect the HPA axis: Assume suppression after 3 weeks of supraphysiologic doses; taper gradually and monitor for adrenal insufficiency
  3. Prevent before you treat: Implement osteoporosis prevention, glucose monitoring, and ophthalmologic surveillance from the outset of chronic therapy
  4. Stress dose liberally: When in doubt, provide stress-dose coverage for hospitalized patients with risk factors for HPA suppression
  5. Individualize therapy: Cookie-cutter approaches fail; tailor dosing, tapering, and monitoring to each patient's unique circumstances

As prescribers, our goal is to harness the anti-inflammatory power of corticosteroids while vigilantly mitigating their substantial risks. By integrating these practical strategies into clinical practice, we can optimize outcomes for patients requiring these indispensable yet challenging medications.


Key Take-Home Points for Critical Care Practitioners

Equivalency conversions must account for both potency and duration of action; dexamethasone's prolonged half-life complicates tapering

HPA axis suppression can occur with >3 weeks of >5 mg/day prednisone; assume suppression in any patient with Cushingoid features

Acute adrenal crisis is life-threatening; maintain low threshold for empiric hydrocortisone 100 mg IV in unexplained shock

Tapering should be gradual, especially below 10 mg/day prednisone; ultra-slow tapers (0.5-1 mg reductions) succeed where conventional tapers fail

Osteoporosis prevention with bisphosphonates should be PROACTIVE in high-risk patients, not reactive after fractures occur

Steroid-induced hyperglycemia requires insulin therapy; NPH insulin matches prednisone's afternoon peak

Stress dosing saves lives: moderate stress needs ~100 mg/day hydrocortisone; major stress needs ~300 mg/day

When uncertain about adrenal sufficiency in a critically ill patient, give hydrocortisone first, ask questions later


References

  1. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. doi:10.1186/1710-1492-9-30

  2. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(2):364-389. doi:10.1210/jc.2015-1710

  3. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521-1537. doi:10.1002/art.40137

  4. Puar TH, Stikkelbroeck NM, Smans LC, Zelissen PM, Hermus AR. Adrenal crisis: still a deadly event in the 21st century. Am J Med. 2016;129(3):339.e1-339.e9. doi:10.1016/j.amjmed.2015.08.021

  5. Minnetti M, Caiulo VA, Hasenmajer V, et al. Susceptibility to infections in patients with Cushing's syndrome or receiving long-term glucocorticoid therapy. Expert Rev Anti Infect Ther. 2022;20(10):1331-1346. doi:10.1080/14787210.2022.2100755

  6. Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Crit Care Med. 2017;45(12):2078-2088. doi:10.1097/CCM.0000000000002737

  7. Strehl C, Ehlers L, Gaber T, Buttgereit F. Glucocorticoids—all-rounders tackling the versatile players of the immune system. Front Immunol. 2019;10:1744. doi:10.3389/fimmu.2019.01744

  8. Joseph RM, Hunter AL, Ray DW, Dixon WG. Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review. Semin Arthritis Rheum. 2016;46(1):133-141. doi:10.1016/j.semarthrit.2016.03.001

  9. Hoes JN, Van der Goes MC, Van Raalte DH, et al. Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis. 2011;70(11):1887-1894. doi:10.1136/ard.2011.151464

  10. Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken). 2013;65(2):294-298. doi:10.1002/acr.21796

  11. Ciriaco M, Ventrice P, Russo G, et al. Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother. 2013;4(Suppl1):S94-S98. doi:10.4103/0976-500X.120975

  12. Hopkins RL, Leinung MC. Exogenous Cushing's syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin North Am. 2005;34(2):371-384. doi:10.1016/j.ecl.2005.01.013

  13. Dinsen S, Baslund B, Klose M, et al. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med. 2013;24(8):714-720. doi:10.1016/j.ejim.2013.05.014

  14. Grossman A, Johannsson G, Quinkler M, Zelissen P. Therapy of endocrine disease: perspectives on the management of adrenal insufficiency: clinical insights from across Europe. Eur J Endocrinol. 2013;169(6):R165-R175. doi:10.1530/EJE-13-0450

  15. Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med. 2008;36(6):1937-1949. doi:10.1097/CCM.0b013e31817603ba

  16. Hasenmajer V, Sbardella E, Sciarra F, Minnetti M, Isidori AM, Venneri MA. The immune system in Cushing's syndrome. Trends Endocrinol Metab. 2020;31(9):655-669. doi:10.1016/j.tem.2020.04.004

  17. Furst DE, Saag KG. Glucocorticoid withdrawal. In: Post TW, ed. UpToDate. UpToDate; 2024. Accessed October 3, 2025.

  18. Wallia A, Parikh ND, Molitch ME, Mahabeleshwar GH. Toward optimal glucose management in patients receiving glucocorticoids. Curr Diab Rep. 2017;17(12):145. doi:10.1007/s11892-017-0963-5

  19. Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93(2):105-111. doi:10.1093/qjmed/93.2.105

  20. Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am J Psychiatry. 2012;169(5):491-497. doi:10.1176/appi.ajp.2011.11071009

  21. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711-1723. doi:10.1056/NEJMra050541

  22. Krasner AS. Glucocorticoid-induced adrenal insufficiency. JAMA. 1999;282(7):671-676. doi:10.1001/jama.282.7.671

  23. Broersen LHA, Pereira AM, Jørgensen JO, Dekkers OM. Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(6):2171-2180. doi:10.1210/jc.2015-1218

  24. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23-43. doi:10.1016/s0163-7258(02)00297-8

  25. Beato M, Sánchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev. 1996;17(6):587-609. doi:10.1210/edrv-17-6-587


Appendix: Quick Reference Tables

Table 2: Rapid Steroid Conversion Calculator

If patient is on: To convert to: Multiply by:
Prednisone Hydrocortisone 4
Prednisone Methylprednisolone 0.8
Prednisone Dexamethasone 0.15 (÷7)
Methylprednisolone Prednisone 1.25
Methylprednisolone Hydrocortisone 5
Methylprednisolone Dexamethasone 0.19 (÷5)
Dexamethasone Prednisone 6.7 (×7)
Dexamethasone Methylprednisolone 5.3 (×5)
Dexamethasone Hydrocortisone 26.7
Hydrocortisone Prednisone 0.25 (÷4)

Table 3: Taper Protocol Summary

Starting Dose (Prednisone Equivalent) Reduction Schedule Monitoring
>40 mg/day Reduce 5-10 mg weekly Symptoms, disease activity
20-40 mg/day Reduce 5 mg every 1-2 weeks Symptoms, disease activity
10-20 mg/day Reduce 2.5 mg every 2 weeks Symptoms, disease activity
5-10 mg/day Reduce 1-2.5 mg every 2-4 weeks Symptoms, AM cortisol at 5 mg
<5 mg/day Reduce 1 mg every 4 weeks OR switch to hydrocortisone taper AM cortisol, ACTH stim test if available

Table 4: Stress Dosing at a Glance

Stress Level Examples Hydrocortisone Dose Duration
Minor Dental cleaning, routine labs, minor infections Continue home dose N/A
Moderate Colonoscopy, pneumonia, cholecystectomy, COVID-19 50 mg IV before, then 25 mg IV q8h 24-48 hours
Major Cardiac surgery, septic shock, major trauma, ARDS 100 mg IV bolus, then 50 mg q6-8h or 200 mg/24h infusion Until stable, then taper over 2-3 days

Table 5: Side Effect Monitoring Checklist

Side Effect Baseline Follow-up Intervention Threshold
Osteoporosis DXA scan, FRAX score DXA every 1-2 years T-score ≤-2.5 or high FRAX → bisphosphonate
Hyperglycemia HbA1c, fasting glucose Weekly glucose checks initially Fasting >126 mg/dL or random >200 mg/dL → treatment
Hypertension BP measurement Every visit >140/90 mmHg → antihypertensive
Cataracts Ophthalmology exam Annual eye exam Visual symptoms → surgical evaluation
Glaucoma IOP measurement Annual or as needed IOP >21 mmHg → ophthalmology referral
Infection TB screening (PPD/IGRA) Clinical vigilance Fever, symptoms → aggressive workup
Psychiatric Mental health history Every visit Severe symptoms → psychiatry, dose reduction

Abbreviations

ACTH = Adrenocorticotropic hormone
ARDS = Acute respiratory distress syndrome
BMD = Bone mineral density
COPD = Chronic obstructive pulmonary disease
CRH = Corticotropin-releasing hormone
DXA = Dual-energy X-ray absorptiometry
FRAX = Fracture Risk Assessment Tool
GIOP = Glucocorticoid-induced osteoporosis
GLP-1 = Glucagon-like peptide-1
HPA = Hypothalamic-pituitary-adrenal
IOP = Intraocular pressure
IV = Intravenous
NPH = Neutral protamine Hagedorn (insulin)
PCP = Pneumocystis jirovecii pneumonia
PO = Per os (oral)
PPI = Proton pump inhibitor
PSC = Posterior subcapsular cataract
PUD = Peptic ulcer disease
TB = Tuberculosis
VFA = Vertebral fracture assessment


Disclosure: The author reports no conflicts of interest.

Author Contributions: This review was prepared as an educational resource for postgraduate medical trainees in critical care medicine.

Acknowledgments: The author thanks the critical care and endocrinology communities for their ongoing contributions to evidence-based corticosteroid management.

Biomarker-based Assessment for Predicting Sepsis-induced Coagulopathy and Outcomes in Intensive Care

  Biomarker-based Assessment for Predicting Sepsis-induced Coagulopathy and Outcomes in Intensive Care Dr Neeraj Manikath , claude.ai Abstr...